A randomised, pragmatic clinical trial of ACUpuncture plus standard care versus standard care alone FOr Chemotherapy Induced peripheral Neuropathy (ACUFOCIN)

por Stringer, Jacqui, Ryder, W. David, Mackereth, Peter A., Misra, Vivek, Wardley, Andrew M.
Publicado 2022

Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treat...

por Verrill, Mark, Wardley, Andrew M., Retzler, Jenny, Smith, Adam B., Bottomley, Catherine, Ní Dhochartaigh, Sorcha, Tran, Irwin, Leslie, Iain, Schmid, Peter
Publicado 2020

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint resul...

por Hiller, Louise, Dunn, Janet A., Loi, Shrushma, Vallier, Anne-Laure, Howe, Donna L., Cameron, David A., Miles, David, Wardley, Andrew M., Earl, Helena M.
Publicado 2018

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study

por Turner, Nicholas C., Laird, A. Douglas, Telli, Melinda L., Rugo, Hope S., Mailliez, Audrey, Ettl, Johannes, Grischke, Eva-Maria, Mina, Lida A., Balmaña, Judith, Fasching, Peter A., Hurvitz, Sara A., Hopkins, Julia F., Albacker, Lee A., Chelliserry, Jijumon, Chen, Ying, Conte, Umberto, Wardley, Andrew M., Robson, Mark E.
Publicado 2023

Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis

por Eyre, Rachel, Alférez, Denis G., Spence, Kath, Kamal, Mohamed, Shaw, Frances L., Simões, Bruno M., Santiago-Gómez, Angélica, Sarmiento-Castro, Aida, Bramley, Maria, Absar, Mohammed, Saad, Zahida, Chatterjee, Sumohan, Kirwan, Cliona, Gandhi, Ashu, Armstrong, Anne C., Wardley, Andrew M., O’Brien, Ciara S., Farnie, Gillian, Howell, Sacha J., Clarke, Robert B.
Publicado 2016

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

por Ring, Alistair, Kilburn, Lucy S., Pearson, Alex, Moretti, Laura, Afshari-Mehr, Angelica, Wardley, Andrew M., Gurel, Bora, Macpherson, Iain R., Riisnaes, Ruth, Baird, Richard D., Martin, Sue, Roylance, Rebecca, Johnson, Hannah, Ferreira, Ana, Winter, Matthew C., Dunne, Kathryn, Copson, Ellen, Hickish, Tamas, Burcombe, Russell, Randle, Kat, Serra, Violeta, Llop-Guevara, Alba, Bliss, Judith M., Turner, Nicolas C.
Publicado 2023

Genomic profile of advanced breast cancer in circulating tumour DNA

por Kingston, Belinda, Cutts, Rosalind J., Bye, Hannah, Beaney, Matthew, Walsh-Crestani, Giselle, Hrebien, Sarah, Swift, Claire, Kilburn, Lucy S., Kernaghan, Sarah, Moretti, Laura, Wilkinson, Katie, Wardley, Andrew M., Macpherson, Iain R., Baird, Richard D., Roylance, Rebecca, Reis-Filho, Jorge S., Hubank, Michael, Faull, Iris, Banks, Kimberly C., Lanman, Richard B., Garcia-Murillas, Isaac, Bliss, Judith M., Ring, Alistair, Turner, Nicholas C.
Publicado 2021

Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA

por Kingston, Belinda, Cutts, Rosalind J., Bye, Hannah, Beaney, Matthew, Walsh-Crestani, Giselle, Hrebien, Sarah, Swift, Claire, Kilburn, Lucy S., Kernaghan, Sarah, Moretti, Laura, Wilkinson, Katie, Wardley, Andrew M., Macpherson, Iain R., Baird, Richard D., Roylance, Rebecca, Reis-Filho, Jorge S., Hubank, Michael, Faull, Iris, Banks, Kimberly C., Lanman, Richard B., Garcia-Murillas, Isaac, Bliss, Judith M., Ring, Alistair, Turner, Nicholas C.
Publicado 2021

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

por Turner, Nicholas C, Kingston, Belinda, Kilburn, Lucy S, Kernaghan, Sarah, Wardley, Andrew M, Macpherson, Iain R, Baird, Richard D, Roylance, Rebecca, Stephens, Peter, Oikonomidou, Olga, Braybrooke, Jeremy P, Tuthill, Mark, Abraham, Jacinta, Winter, Matthew C, Bye, Hannah, Hubank, Michael, Gevensleben, Heidrun, Cutts, Ros, Snowdon, Claire, Rea, Daniel, Cameron, David, Shaaban, Abeer, Randle, Katrina, Martin, Sue, Wilkinson, Katie, Moretti, Laura, Bliss, Judith M, Ring, Alistair
Publicado 2020

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

por Earl, Helena M, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Howe, Donna, Raynes, Kerry, Higgins, Helen B, Wilcox, Maggie, Plummer, Chris, Mansi, Janine, Gounaris, Ioannis, Mahler–Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Abraham, Jean E, Caldas, Carlos, Hall, Peter S, McCabe, Christopher, Hulme, Claire, Miles, David, Wardley, Andrew M, Cameron, David A, Dunn, Janet A
Publicado 2019